Clinical trials: Neuroendocrine Tumors With Metastasis
Cancer
Thalidomide and Docetaxel in Treating Patients With Advanced Cancer
RATIONALE: Thalidomide may stop the growth of cancer by stopping blood flow to the tumor. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.
- Trial name
- NCT00049296
- Testing
- docetaxel, thalidomide
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Case Comprehensive Cancer Center
Uveal Melanoma
Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma
This is a randomized, multi-center, open-label study of adjuvant darovasertib in participants with non-metastatic uveal melanoma (OptimUM-11)
- Trial name
- NCT07804186
- Testing
- Darovasertib, Crizotinib (Xalkori)
- Where
- 13 sites in United States, Canada
- Volunteers
- 450 people
- Sponsor
- IDEAYA Biosciences
Melanoma
A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation
The purpose of this study is to determine whether nilotinib is efficacious in the treatment of metastatic and/or inoperable melanoma harboring a c-Kit mutation.
- Trial name
- TEAM (NCT01028222)
- Testing
- Nilotinib, DTIC
- Where
- 49 sites in United States, Argentina and 12 more
- Volunteers
- 55 people
- Sponsor
- Novartis Pharmaceuticals
Neuroendocrine Tumors
Asian Investigation of Lanreotide Autogel® in the Management of GEP-NETs
Lanreotide Autogel® has been established as a standard of care for patients with locally advanced or metastatic GEP-NETs based on the success of CLARINET trial.
- Trial name
- AIM-NETs (NCT04696042)
- Testing
- Lanreotide autogel
- Where
- South Korea
- Volunteers
- 71 people
- Sponsor
- Asan Medical Center
Cervix Cancer, Cadonilimab
Evaluation of AK104 (Cadonilimab) Combined with Chemotherapy for Recurrent or Metastatic Small Cell Neuroendocrine Carcinoma of the Cervix
The goal of this clinical trial is to evaluate the safety and effectiveness of AK104 (Cadonilimab) combined with chemotherapy (cisplatin or carboplatin, and etoposide) for the treatment of recurrent or metastatic small cell…
- Conditions
- Cervix Cancer, Cadonilimab, Small Cell Neuroendocrine Carcinoma of the Cervix
- Trial name
- NCT06810895
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Ding Ma
Breast Cancer, Skin Cancer
Safety Study Using Photodynamic Therapy Light Therapy for Patients With Chest Wall Progression of Breast Cancer and Satellite Metastases of Melanoma
This research is intended to explore a new approach to therapy when breast cancer recurs in the skin. The treatment, known as continuous low-irradiance photodynamic therapy, or CLIPT, has shown great promise in animal studies.
- Trial name
- CLIPT (NCT00862901)
- Testing
- CLIPT patch
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Tufts Medical Center
Stage IV Skin Melanoma
Translational Study for BRAFV600 Serum and Plasma Determination in Patients With BRAFV600 Metastatic Melanoma
This is a multi-centric translational study with biological samples collection. The aim of this study is to validate a method to detect BRAFV600 in blood samples.
- Trial name
- BRAFV600 (NCT01960634)
- Where
- 13 sites in Spain
- Volunteers
- 58 people
- Sponsor
- Grupo Español Multidisciplinar de Melanoma
NSCLC, Melanoma
A Phase 1/2 Study of BA3071 in Patients With Solid Tumors
The objective of this study is to assess safety and efficacy of BA3071 in solid tumors
- Trial name
- NCT05180799
- Testing
- BA3071, Nivolumab, Pembrolizumab
- Where
- 12 sites in United States, Australia
- Volunteers
- 320 people
- Sponsor
- BioAtla, Inc.
Solid Tumor, Non-Small Cell Lung Cancer
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
This is a Phase 1/2, open-label, non-randomized, 4-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX 106 administered as a single agent or in…
- Conditions
- Solid Tumor, Non-Small Cell Lung Cancer, Head and Neck Cancer, Melanoma
- Trial name
- NCT04198766
- Testing
- INBRX-106 - Hexavalent OX40 agonist antibody, pembrolizumab 200 mg, pembrolizumab 400 mg
- Where
- 60 sites in United States, Singapore and 2 more
- Volunteers
- 340 people
- Sponsor
- Inhibrx Biosciences, Inc
Melanoma
Evaluating the Safety and the Biological Effects of Intratumoral Interferon Gamma and a Peptide-Based Vaccine in Patients With Melanoma
The goals of this study are to evaluate 1) the safety of administration of intratumoral interferon gamma with a peptide-based vaccine, in patients with melanoma and 2) the biological effects of the vaccine.
- Trial name
- Mel 51 (NCT00977145)
- Testing
- A combination of intratumoral IFN-gamma plus systemic vaccination with MELITAC 12.1
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Craig L Slingluff, Jr
Melanoma (Skin)
Pegylated Arginine Deiminase in Treating Patients With Metastatic Melanoma That Cannot Be Removed by Surgery
RATIONALE: Pegylated arginine deiminase may stop the growth of tumor cells by taking away an amino acid needed for cell growth. PURPOSE: This phase II trial is studying how well pegylated arginine deiminase works in treating…
- Trial name
- NCT00450372
- Testing
- ADI-PEG-20, Pharmacology Studies
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- University of Miami
Metastatic Melanoma
A Study of Tasisulam in Treating Participants With Malignant Melanoma
The primary purpose of this study is to determine the objective response rate (complete and partial response) for participants who receive tasisulam after one prior systemic treatment for unresectable or metastatic melanoma.
- Trial name
- NCT00383292
- Testing
- tasisulam
- Where
- 13 sites in United States, Australia
- Volunteers
- 130 people
- Sponsor
- Eli Lilly and Company
Cutaneous Malignant Melanoma
Efficacy and Safety of Nintedanib Combined With Paclitaxel Chemotherapy for Patients With BRAF wt Metastatic Melanoma
This is a multicenter, randomized, double-blind, placebo-controlled phase I/II trial designed to characterize the safety and estimate the efficacy of nintedanib when combined with paclitaxel chemotherapy compared with paclitaxel…
- Trial name
- NIPAWILMA (NCT02308553)
- Testing
- Nintedanib, Paclitaxel
- Where
- 10 sites in Germany
- Volunteers
- 33 people
- Sponsor
- Prof. Dr. med. Dirk Schadendorf
Cancer
Investigate Safety, Pharmacokinetics and Pharmacodynamics of GSK2118436 & GSK1120212
This was an open-label, dose escalation study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK2118436 and GSK1120212 in combination. This study was designed in four parts.
- Trial name
- NCT01072175
- Testing
- GSK2118436, GSK1120212
- Where
- 15 sites in United States, Australia
- Volunteers
- 430 people
- Sponsor
- Novartis Pharmaceuticals
Metastatic Melanoma (Stage IIIC Non-résécable or no Surgically Curable or Stage IV With Classification AJCC)
Pilot Study Evaluating the Efficacy and Safety of Metformin in Melanoma
In western countries, melanoma represents a major mistake of public health by its frequency, lethality and the increasing of incidence. Surgery can cure melanoma diagnosed very early.
- Trial name
- NCT01840007
- Testing
- Metformin Group
- Where
- 2 sites in France
- Volunteers
- 20 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Neuroendocrine Tumors
Holmium-166-radioembolization in NET After Lutetium-177-dotatate; an Efficacy Study
Patients with gastroenteropancreatic neuroendocrine tumours (NET) often die from intrahepatic disease or are excluded from liver-directed treatment because of extrahepatic disease.
- Trial name
- HEPAR_Plus (NCT02067988)
- Testing
- Holmium-166 microspheres hepatic radioembolization.
- Where
- Netherlands
- Volunteers
- 34 people
- Sponsor
- UMC Utrecht
Cutaneous Squamous Cell Carcinoma, SCC - Squamous Cell Carcinoma
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
Participants of this study will have a diagnosis of a solid tumor cancer that has come back to its original location or spread beyond its original location (advanced), came back (relapsed) or worsened (refractory) after standard…
- Conditions
- Cutaneous Squamous Cell Carcinoma, SCC - Squamous Cell Carcinoma, Basal Cell Carcinoma, BCC
- Trial name
- NCT05859074
- Testing
- MQ719, Pembrolizumab
- Where
- 7 sites in United States
- Volunteers
- 56 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Melanoma, Metastasis
Encorafenib, Binimetinib and Palbociclib in BRAF-mutant Metastatic Melanoma CELEBRATE
This is an open-label, phase IB, non-randomised study consisting of a dose escalation phase and expansion phase, evaluating the safety, tolerability and preliminary efficacy of the combination of encorafenib, binimetinib and…
- Trial name
- CELEBRATE (NCT04720768)
- Testing
- Binimetinib, Encorafenib, Palbociclib
- Where
- 4 sites in Australia
- Volunteers
- 78 people
- Sponsor
- Peter MacCallum Cancer Centre, Australia
Non-Small Cell Lung Cancer, Melanoma
A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma
To characterize safety and tolerability and identify a recommended dose and regimen for the LXH254 in combination with LTT462 or trametinib or ribociclib.
- Trial name
- NCT02974725
- Testing
- LXH254, LTT462, Trametinib
- Where
- 32 sites in United States, Australia and 9 more
- Volunteers
- 241 people
- Sponsor
- Novartis Pharmaceuticals
Neuroendocrine Carcinomas
Cisplatinum and Everolimus in Patients With Metastatic or Unresectable NEC of Extrapulmonary Origin
Phase II, open-label, multicentre national study. Patients with metastatic neuroendocrine carcinomas of extrapulmonary origin will be eligible.
- Trial name
- NCT02695459
- Testing
- cisplatinum and everolimus
- Where
- 3 sites in Netherlands
- Volunteers
- 39 people
- Sponsor
- The Netherlands Cancer Institute
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.